Volumetric abnormalities of thalamic subnuclei in medication-overuse headache

Zhiye Chen1,2,3, Zhihua Jia2, Xiaoyan Chen2, Mengqi Liu1,3, Shuangfeng Liu1, Lin Ma* and Shengyuan Yu2*

Abstract

Background: The thalamus exerts a pivotal role in pain processing and cortical excitability control and a previous voxel-based morphometry study confirmed increased volume in bilateral thalamus in medication-overuse headache (MOH). The aim of this study is to investigate altered thalamic subnuclei volume in MOH compared with normal controls, and to evaluate the relationship of each thalamic subnuclei volume with the clinical variables.

Methods: High resolution three-dimensional T1-weighted fast spoiled gradient recalled echo MR images were obtained from 27 patients with MOH and 27 normal controls (NC). Thalamic subnuclei templates were created based on Talairach template with MNI space transformation, and the individual thalamic subnuclei templates were generated by applying the deformation field from structural image segment to the thalamic subnuclei templates, and then individual thalamic subnuclei volume were calculated.

Results: The whole thalamus and each thalamic subnuclei presented increased volume compared with NC (P < 0.05). The correlation analysis demonstrated that the whole thalamus volume and each thalamic subnuclei volume showed a negative relationship with HAMD scores (P < 0.05), and no any correlation with HAMA, VAS score and disease duration (P > 0.05).

Conclusion: Increased gray matter volume in the whole thalamus and all the thalamic subnuclei may reflect central sensitization and higher-order of pain alteration in MOH. These structural changes in the thalamus may also be influenced by mood disturbances related to the MOH.

Keywords: Medication-overuse headache, Migraine, Thalamus, Magnetic resonance imaging

Background

Medication-overuse headache (MOH) was defined as a headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute or symptomatic headache medication for more than 3 months [1]. MOH has a prevalence of 0.6–2.0% in the general population [2, 3], and was associated with mood disorders in 27–85% and anxiety disorders in 61–83%. MOH patients experience reduced quality of life compared with those who do not suffer from headaches [4]. A pre-existing headache disorder seems to be required to develop MOH [5]. It is well known that previous primary headaches such as migraine are the most important risk factors for the development of MOH, 50%–70% MOH have co-occurrence of migraine in population-based studies [6, 7]. Many psychosocial and socioeconomic factors which are prevailed in patients with chronic forms of headache are also associated with MOH. However, the mechanism behind how chronic exposure to abortive medication leads to MOH remains unclear. Alteration of cortical neuronal excitability, central sensitization involving the trigeminal nociceptive system have been suggested to play a part in the pathophysiology of MOH [8].

The thalamus contains third-order trigeminovascular nociceptive neurons and exerts a pivotal role in pain processing and cortical excitability control [9, 10]. Microstructural and functional alterations of the thalamus have been found in migraine patients [11, 12]. Significant volume reductions of the following thalamic...
nuclei densely connected to the limbic system were observed in migraines: central nuclear complex, anterior nucleus and lateral dorsal nucleus, supported that higher-order integration systems are altered in migraine [11]. Increased iron deposition and myelin content/cellularity in the thalamus of migraine with aura patients compared with migraine without aura patients and healthy controls were found, may underlie abnormal cortical excitability control leading to cortical spreading depression and visual aura [13]. A voxel-based morphometry (VBM) study identified increased gray matter volume in bilateral thalamus in MOH patients [14]. Although it was demonstrated that periaqueductal gray (PAG) volume gain [15] and altered intrinsic functional connectivity architecture [16] were confirmed in MOH patients in our previous study, however, it was not known that how the thalamic subnuclei volume changed in MOH up to now.

Up to now, several documents had recognized that thalamic subnuclei were segmented based on diffusion tensor imaging [17, 18], and thalamic nuclei densely connected to the limbic system were observed in migraines [11]. Therefore, morphology analysis of thalamic subnuclei would provide more information in the understanding of neuromechanism of MOH.

The main objective of the current study was to investigate the altered thalamic subnuclei volume in MOH compared with normal controls, and to further evaluate the relationship of each thalamic subnuclei volume with the clinical variables.

**Methods**

**Subjects**

This study was approved by the ethics committee of the Chinese PLA General Hospital, and written informed consent was obtained from the subjects according to the Declaration of Helsinki. Twenty-seven MOH patients were consecutively recruited from the headache center, Chinese PLA General Hospital. The included criteria of MOH included as follows: (1) All patients with both, MOH and migraine; (2) The diagnosis of 8.2 MOH, 1.1 and 1.2 migraine based on the International Classification of Headache Disorders, third Edition (beta version) (ICHD-III beta); (3) Without migraine preventive medication in the past 3 months. The excluded criteria included as follows: (1) With chronic disorders, including hypertension, diabetes mellitus, cardiovascular diseases, etc.; (2) With cranium trauma, psychotic disorder, and regular use of a psychoactive or hormone medication. Part of MOH patients were overlapping with our previous studies [15, 16]. Twenty-seven normal controls (NCs) were recruited, who should never have any primary headache disorders or other types of headache in the past year, and had the same exclusion criteria with MOH patients. Headache information were registered and evaluated in our headache database. All the patients were given with the Visual Analogue Scale (VAS) evaluation. Additionally, we used the Hamilton Anxiety Scale (HAMA) [19] scale to assess the anxiety, the Hamilton Depression Scale) [20] to assess the depression, and the Mini-mental State Examination (MMSE) [21] to assess the cognitive function of all the participants. MRI scans were taken in the interictal stage at least three days after a migraine attack for MOH patients. Alcohol, nicotine, caffeine, and other substances were avoided for at least 12 h before MRI examination.

**MRI acquisition**

MRI data were obtained by a conventional eight-channel quadrature head coil from a GE 3.0 T MR system (DISCOVERY MR750, GE Healthcare, Milwaukee, WI, USA). All subjects were instructed to lie in a supine position, and formed padding was used to limit head movement. An axial three-dimensional T1-weighted fast spoiled gradient recalled echo (3D T1-FSPGR) sequence was performed to acquire the brain structure images. The 3D T1-FSPGR parameters were listed as follows: TR (repetition time) = 6.3 ms, TE (echo time) = 2.8 ms, flip angle = 150°, FOV (field of view) = 25.6 cm × 25.6 cm, Matrix = 256 × 256, NEX (number of acquisition) = 1. All the subjects were performed the same imaging protocols, and the subjects with structural damage would be excluded.

**Image processing**

Image processing mainly included the following steps: (1) Convert Talairach template [22] into MNI space, and the thalamic subnuclei templates were created using rest software [23]. The thalamic subnuclei [11] included following subregions: left/right ventral posterior lateral nucleus (L_VPL/R_VPL), left/right ventral posterior medial nucleus (L_VPM/R_VPM), left/right dorsomedial nucleus (L_DM/R_DM), left/right ventral lateral nucleus (L_VL/R_VL), left/right ventral anterior nucleus (L_VA/R_VA), and left/right anterior nucleus (L_AN/R_AN). (Fig. 1). (2) The individual structural images were segmented by the new segment tool embedded in SPM 12 software (http://www.fil.ion.ucl.ac.uk/spm), and the inverse deformation field was generated (iy_subjectID.nii). Then, the standard thalamic subnuclei were applied with the inverse deformation with pullback strategy, which would generate the individual thalamic subnuclei masks [15] (Fig. 2). Each individual thalamic subnucleus segmentations were visually inspected to confirm anatomical accuracy by one experienced radiologist. (3) The volume of individual thalamic subnuclei were measured by ITK-SNAP (V3.6.0) software (http://www.itksnap.org/pmwiki/pmwiki.php).
Statistical analysis

The statistical analysis was performed by using PASW Statistics 18.0. The age, MMSE, HAMD, and HAMA were performed with independent samples T test, and sex was performed with Chi-Square test. The significance differences of whole thalamus and thalamic subnuclei volume were computed using analysis of covariance with the age and sex as covariates between MOH group and NC group. The Pearson’s correlation analysis was applied between thalamic volume and the clinical variables (including disease duration, VAS) in MOH. Significant difference was set at a P value of <0.05.

Results

Comparison of clinical characteristics between MOH and NC

The current study included 27 MOH patients (F/M = 20/7) and 27 normal controls (F/M = 19/8). The age, sex and MMSE showed no significant difference between MOH and NC (P > 0.05). There was a significant HAMD and HAMA between MOH (20.85 ± 12.67 and 17.70 ± 8.63) and NC (7.32 ± 4.26 and 9.78 ± 2.91) (P < 0.05) (Table 1).

Comparison of thalamic subnuclei volume between MOH and NC

Table 2 demonstrated that all the thalamic subnuclei presented increased volume in MOH compared with NC (P < 0.05). Bilateral whole thalamus also showed increased volume in MOH (L_T, 3.365 ± 0.291 ml, R_T, 3.312 ± 0.288 ml) compared with NC (L_T, 3.237 ± 0.249 ml, R_T, 3.190 ± 0.241 ml) (P < 0.05) (Fig. 3).

Correlation analysis between thalamic subnuclei volume and the clinical variable

Figure 4 demonstrated that all the thalamic subnuclei volume were significantly negatively related with HAMD score (P < 0.05), and there were not significant relationship between all the thalamic subnuclei and the other clinical variables including HAMA, VAS and disease duration (P > 0.05) (Table 3).

Discussion

Our study aimed to identify morphological changes of thalamic subnuclei in MOH and try to reveal more

| MOH | NC | T value | P value |
|-----|----|---------|---------|
| Num(F/M) | 27(20/7) | 27(19/8) | 0.092* | 0.761 |
| Age | 39.93 ± 9.75 | 43.04 ± 10.82 | 2.007 | 0.272 |
| MMSE | 27.41 ± 3.74 | 28.19 ± 1.00 | 2.007 | 0.302 |
| HAMD | 20.85 ± 12.67 | 7.32 ± 4.26 | 2.008 | 0.000 |
| HAMA | 17.70 ± 8.63 | 9.78 ± 2.91 | 2.007 | 0.000 |
| DD | 18.07 ± 9.85 | NA | NA | NA |
| VAS | 8.26 ± 1.46 | NA | NA | NA |

*Chi-square test. MOH medication-overuse headache, NC normal control, DD disease duration, VAS Visual Analogue Scale, HAMA Hamilton Anxiety Scale, HAMD Hamilton Depression Scale, MMSE Mini-mental State Examination, NA not available
information about the neuromechanism of MOH. In our study, psychiatric evaluation revealed that the majority of patients had comorbid psychiatric conditions, containing both anxiety and depressive disorders, which is accordant with epidemiologic studies [24, 25]. A previous study showed MOH patients have a greater risk of suffering from anxiety and depression than episodic migraine, and psychiatric disorders occurred significantly more often before the transformation from migraine into MOH than after [26]. It deduced that these disorders may be a risk factor for the evolution of migraine into MOH. Another follow-up study identified several risk factors for MOH among people with chronic headache, including increased Hospital Anxiety and Depression Scale score [27]. However, depression and anxiety disorders are associated with both migraine and non-migrainous headache, and this was related to the headache frequency rather than headache diagnosis in another research, so the relationship between psychiatric disorders and MOH may be comorbidity [28]. The cause-effect relationship needs further longitudinal study.

Consistent with the previous study [14], we found increased whole thalamus volume bilaterally in the MOH. An increase in GMV may reflect structural brain plasticity as a result of exercise and learning [29]. Gray matter volume increase in the thalamus has also been found in chronic pain conditions such as back pain [30] and chronic post-traumatic headache [31]. Increased GMV in the thalamus might reflect central sensitization in chronic pain states. However, studies about the thalamic subnuclei volume in these chronic pain conditions have not been found. If the morphological abnormalities of thalamic subnuclei are specific to MOH or if the morphological abnormalities of thalamic can be normalized as cephalic, extra-cephalic pressure-pain thresholds and pain-related cortical potentials in MOH patients after withdrawal of the overused medication needs further study [31, 32].

| Table 2 | The volume comparison of thalamic subnuclei(ml) between MOH and NC |
|---------|---------------------------------------------------------------|
|         | MOH              | NC               | F value | P value |
| L_AN    | 0.195 ± 0.017    | 0.187 ± 0.015    | 6.788   | 0.012   |
| L_DM    | 1.164 ± 0.106    | 1.123 ± 0.093    | 4.627   | 0.036   |
| L_VA    | 0.324 ± 0.027    | 0.311 ± 0.023    | 6.974   | 0.011   |
| L_VL    | 1.056 ± 0.090    | 1.014 ± 0.076    | 7.570   | 0.008   |
| L_VPL   | 0.375 ± 0.033    | 0.360 ± 0.027    | 7.546   | 0.008   |
| L_VPM   | 0.253 ± 0.022    | 0.243 ± 0.018    | 7.087   | 0.010   |
| L_T     | 3.365 ± 0.291    | 3.237 ± 0.249    | 6.474   | 0.014   |
| R_AN    | 0.182 ± 0.016    | 0.175 ± 0.013    | 6.657   | 0.013   |
| R_DM    | 1.845 ± 0.112    | 1.143 ± 0.095    | 4.529   | 0.038   |
| R_VA    | 0.319 ± 0.027    | 0.306 ± 0.022    | 8.365   | 0.006   |
| R_VL    | 0.997 ± 0.083    | 0.958 ± 0.069    | 7.607   | 0.008   |
| R_VPL   | 0.393 ± 0.034    | 0.379 ± 0.028    | 6.059   | 0.017   |
| R_VPM   | 0.236 ± 0.021    | 0.229 ± 0.017    | 4.937   | 0.031   |
| R_T     | 3.312 ± 0.288    | 3.190 ± 0.241    | 6.210   | 0.016   |

L left, R right, AN anterior nucleus, DM dorsomedial nucleus, VA ventral anterior nucleus, VL ventral lateral nucleus, VPL ventral posterior lateral nucleus, VPM ventral posterior medial nucleus, T thalamus
Increased gray matter volume in DM, VPL and VPM may indicate higher-order of pain are altered in MOH.

In our study, we did not find a relation between the volumes of thalamic nuclei and clinical features, such as VAS or the duration of the disorder. It suggests that increased gray matter volume in thalamus may relate to the genetic background of patients with MOH. We observed negative associations between HAMD scores and gray matter volume in all the thalamus subnuclei in patients, suggesting that these structural changes may also

Table 3 The correlation of thalamic subnuclei volume with the clinical variables

|       | HAMD  |      | HAMA  |      | VAS   |      | DD    |      |
|-------|-------|------|-------|------|-------|------|-------|------|
|       |       |      |       |      |       |      |       |      |
| L_AN  | −0.469| 0.016| −0.159| 0.439| 0.002 | 0.991| −0.018| 0.929|
| L_DM  | −0.466| 0.017| −0.171| 0.404| 0.025 | 0.902| 0.071 | 0.724|
| L_VA  | −0.467| 0.016| −0.192| 0.347| −0.073| 0.718| −0.009| 0.966|
| L_VL  | −0.468| 0.016| −0.186| 0.363| −0.069| 0.733| −0.005| 0.981|
| L_VPL | −0.460| 0.018| −0.178| 0.384| −0.099| 0.623| 0.026 | 0.897|
| L_VPM | −0.453| 0.020| −0.161| 0.434| −0.087| 0.668| 0.035 | 0.863|
| L_T   | −0.471| 0.015| −0.180| 0.380| −0.037| 0.856| 0.028 | 0.889|
| R_AN  | −0.491| 0.011| −0.165| 0.420| 0.027 | 0.892| −0.013| 0.948|
| R_DM  | −0.502| 0.009| −0.205| 0.316| 0.014 | 0.946| 0.077 | 0.701|
| R_VA  | −0.512| 0.008| −0.229| 0.261| −0.058| 0.775| 0.018 | 0.931|
| R_VL  | −0.514| 0.007| −0.217| 0.288| −0.064| 0.753| 0.037 | 0.853|
| R_VPL | −0.506| 0.008| −0.215| 0.292| −0.109| 0.589| 0.052 | 0.796|
| R_VPM | −0.494| 0.010| −0.200| 0.329| −0.108| 0.592| 0.055 | 0.786|
| R_T   | −0.513| 0.007| −0.213| 0.297| −0.037| 0.853| 0.052 | 0.798|

L, left; R, right; AN, anterior nucleus; DM, dorsomedial nucleus; VA, ventral anterior nucleus; VL, ventral lateral nucleus; VPL, ventral posterior lateral nucleus; VPM, ventral posterior medial nucleus; T, thalamus; HAMD, Hamilton Depression Scale
be influenced by mood disturbances related to the disorder [37].

**Conclusions**

In conclusion, increased gray matter volume in the whole thalamus and all the thalamus subnuclei may reflect central sensitization and higher-order of pain alteration in MOH. These structural changes in the thalamus may also be influenced by mood disturbances related to the MOH. Whether the observed morphological abnormalities in MOH can be reversed after withdrawal of the overused medication remains unclear.

**Abbreviations**

AN: Anterior nucleus; DM: Dorsomedial nucleus; MOH: Medication-overuse headache; NC: Normal controls; VA: Ventral anterior nucleus; VL: Ventral lateral nucleus; VPL: Ventral posterior lateral nucleus; VPM: Ventral posterior medial nucleus

**Acknowledgments**

This work was supported by the Special Financial Grant from the China Postdoctoral Science Foundation (2014 T70960) and the Foundation for Medical and health Sci & Tech innovation Project of Sanya (2016YW37).

**Authors’ contributions**

Category 1: (a) Conception and Design: LM; SYY; (b) Acquisition of Data: ZYC; MQL; SFL; XYC. Category 2: (a) Analysis and Interpretation of Data: ZYC

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Radiology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. 2Department of Neurology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. 3Department of Radiology, Hainan Branch of Chinese PLA General Hospital, Sanya 572013, China.

**Received:** 27 June 2017 **Accepted:** 31 July 2017 **Published online:** 14 August 2017

**References**

1. Headache Classification Committee of the International Headache S (2013). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808

2. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J et al (2012) The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 52:582–591

3. Evers S, Marzinik M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391–401

4. Lanteri-Minet M, Douru G, Mudge M, Cotrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850

5. Bahra A, Walsh M, Monen S, Goadby PJ (2003) Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 43:170–190

6. Bigal ME, Lipton RB (2008) Excessive acute migraine medication use and migraine progression. Neurology 71:1821–1828

7. Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: a review. J Pain Res 7:367–378

8. Bongsebandhu-phubhabdi S, Srikatkhachorn A (2012) Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep 16:110–115

9. Borsook D (2012) Neurological diseases and pain. Brain 135:320–344

10. Poulet JF, Fernandez LM, Crochet S, Petersen CC (2012) Thalamic control of cortical states. Nat Neurosci 15:370–372

11. Magon S, May A, Stanekwitz A, Goadby PJ, Tso AR, Ashina M et al (2015) Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 tesla. J Neurosci 35:13800–13806

12. Afirdi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, Goadby PJ (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62:1270–1275

13. Granzeria C, Dadducci A, Romascano D, Roche A, Helms G, Krueger G, Hadjikhani N (2014) Structural abnormalities in the thalamus of migraineurs with aura: a multiparametric study at 3 T. J Hum Brain Mapp 35:1461–1468

14. Riederer F, Marti M, Luechinger R, Lanzenberger R, von Meyenburg J, Gantenbein AR et al (2012) Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry 13:517–525

15. Chen Z, Chen X, Liu M, Liu S, Ma L, Yu S (2017) Volume gain of periaqueductal gray in medication-overuse headache. J Headache Pain. 18:12

16. Chen Z, Chen X, Liu M, Dong Z, Ma L, Yu S (2017) Altered functional connectivity architecture of the brain in medication overuse headache using resting state fMRI. J Headache Pain. 18:25

17. Wiegel MR, Tuch DS, Larson HB, Wedeen VJ (2011) Automatic segmentation of thalamic nuclei from diffusion tensor magnetic resonance imaging. NeuroImage 19:391–401

18. Duan Y, Li X, Ji Y (2007) Thalamic segmentation from diffusion tensor magnetic resonance imaging. Int J Biomed Imaging 2007:90216

19. Maer W, Buller R, Philipp M, Heuser I (1988) The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14:61–68

20. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278

21. Galea M, Woodward M (2005) Mini-mental state examination (MMSE). Aust J Ageing 24:26

22. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L et al (2003) Automated tool kit for resting-state functional magnetic resonance imaging data processing. PLoS One 6:20301

23. Francoise Radat MD, Dina Sakh MD, Gina Lutz MD, Amrani ME, Maurice Ferreri MD, Marie-Germaine Boussier MD (1999) Psychiatric comorbidity is related to headache induced by chronic substance use in Migraineurs. Headache 39:477–480

24. Cupini LM, De MM, Costa C, Mancini M, Eusebi P, Sarchielli P, Calabresi P (2009) Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache 49:1005–1013

25. Radat F, Creach S, Swendsen JD, Laftatou I, Iachabal S, Dousset V, Heny P (2005) Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 25:519–522

26. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA (2012) Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies Pain 153:56–61

27. Zwart JA, Dyb G, Hagen K, Odegard KJ, Dahl AA, Bovim G, Stovner LJ (2003) Depression and anxiety disorders associated with headache frequency. The Nord-Trondelag Health Study Eur J Neurol 10:147–152

28. May A (2009) Morphing voxels: the hype around structural imaging of headache patients. Brain 132:1419–1425

29. Schmidt-Willeke T, Leinsich E, Gansbauer S, Draganski B, Bogdahn U, Altmann J, May A (2006) Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain 125:89–97

30. Ayzenberg I, Obermann M, Nyhus P, Gastpar M, Linrmroth V, Dierer HC et al (2006) Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 26:1106–1114

31. Munksgaard SB, Bendtsen L, Jensen RH (2013) Modulation of central sensitization by detoxification in MOH: results of a 12-month detoxification study. Cephalalgia 33:444–453
33. Child ND, Benarroch EE (2013) Anterior nucleus of the thalamus: functional organization and clinical implications. Neurology 81:1869–1876
34. Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A (2011) Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 12:115–125
35. Ide S, Kakeda S, Korogi Y (2015) Anatomy of the thalamus. Brain Nerve 67:1459–1469
36. Yen CT, Lu PL (2013) Thalamus and pain. Acta Anaesthesiol Taiwanica 51:73–80
37. Hubbard CS, Khan SA, Keaser ML, Mathur VA, Goyal M, Seminowicz DA (2014) Altered brain structure and function correlate with disease severity and pain catastrophizing in migraine patients. eNeuro 1(e20):14